BioNxt Reports Successful Results From ODF Cladribine PK Study

Rhea-AI Summary

BioNxt Solutions Inc. completes a successful comparative pharmacokinetic study for its Cladribine oral dissolvable film product for Multiple Sclerosis treatment, demonstrating rapid absorption and systemic exposure comparable to the reference drug. The results pave the way for further development and expansion into high-value drug formulations. BioNxt aims to capitalize on the growing market for MS drugs, with the potential to tap into a market expected to reach USD 41 billion by 2033.

Positive

• Successful completion of the comparative pharmacokinetic study for Cladribine ODF product
• Promising results showing rapid absorption and systemic exposure comparable to the reference drug
• Validation of ODF platform as an effective drug delivery system for cytostatic drugs
• Strengthening of Cladribine ODF patent position
• Expansion opportunities into additional ODF drug formulations for high-value and toxic drugs
• Development of a proprietary hybrid-generic ODF Cladribine dosage form for the MS market
• Approval of Cladribine tablets in over 75 countries with annual sales exceeding one billion USD
• Positive outlook for the MS drug market with a global market expected to reach USD 41 billion by 2033
• Accelerated Cladribine ODF program with GMP product development and batch production planned
• Filing of provisional patent applications for Cladribine ODF with potential patent protection until 2044
• Global pharmaceutical drug delivery market size expected to surpass USD 2,047 billion by 2030

Negative

• None.

VANCOUVER, BC / ACCESSWIRE / March 13, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to report that the comparative pharmacokinetic ("PK") study for its oral dissolvable film ("ODF") based proprietary Cladribine product for the treatment of Multiple Sclerosis ("MS") has been completed and results received by the Company. The animal PK study results are highly promising and demonstrated comparable rapid absorption and systemic exposure between the Company's ODF product and the name-brand reference drug in all samples.

"These results are a significant milestone for BioNxt. We have demonstrated that our ODF platform is an effective drug delivery system for cytostatic drugs via transmucosal absorption," said Hugh Rogers, CEO of BioNxt. "With our recently obtained toxicology data, the PK results allow us to strengthen the Company's Cladribine ODF patent position and proceed immediately to a PK study in humans. These exciting results validate the potential for BioNxt to immediately expand into additional ODF drug formulations for similar, high-value and highly toxic drugs."

BioNxt is developing a 100% owned and proprietary hybrid-generic ODF Cladribine dosage form, directed at the MS market. Cladribine tablets are currently approved for use in over 75 countries, including by the United States Food and Drug Administration ("FDA") and the European Medicines Agency ("EMA"), with annual sales in excess of one billion USD. Cladribine tablets are approved for several indications, namely highly active forms of relapsing-remitting MS and certain forms of leukemia. MS represents the largest market segment for the sale of Cladribine with approximately 2.3 million people living with MS worldwide, with the highest prevalence in North America and Europe, noted by Atlas of MS. The global Multiple Sclerosis drug market is expected to top USD 41 billion by 2033 according to Market.us.

The comparative PK study was carried out by a European contract research organization in accordance with EU medical regulatory guidelines using animal models and a single administration of either sublingual (ODF) or oral (tablet) Cladribine. Blood testing and analysis was carried out pre-dose and at up to six time points after administration using blood aliquots. The animal PK study results closely follows the unanimously successful results of the ODF Cladribine animal toxicity study, announced February 7, 2024: positive results were observed in all study participants with no adverse clinical abnormalities or indications of toxicity observed in the study after consecutive days of dosing.

BioNxt has accelerated its Cladribine ODF program in a priority manner with GMP product development and batch production planned for Q1 and Q2 2024 with the European Investigational Medicinal Product Dossier (IMPD) preparation and submission planned for Q2 2024.

The Company has filed Cladribine ODF-related provisional patent applications with three to four patent applications expected to be on file in major international jurisdictions by late 2024 to early 2025 with potential patent protection extending to 2044.

BioNxt's wholly owned subsidiary is a German narcotics manufacturer, developer, and researcher located in the district of Biberach, Baden-Württemberg, Germany. For over a decade, the company and its team have been leaders in the design, testing and manufacture of innovative, non-invasive drug delivery systems, particularly transdermal patches and sublingual strips for the delivery of active pharmaceutical ingredients for the treatment of pain and neurological conditions. According to Precedence Research, the global pharmaceutical drug delivery market size was valued at USD 1,525 billion in 2022 and expected to surpass approximately USD 2,047 billion by 2030.

About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience accelerator focused on next-generation drug formulations and delivery systems, diagnostic screening tests, and new active pharmaceutical production and evaluation, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization and clinical evaluation of emerging active pharmaceutical ingredients for neurological applications. The Company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets.

BioNxt Solutions Inc.
Hugh Rogers, CEO and Director
Email: info@bionxt.com
Phone: +1 780-818-6422

Cautionary Statement Regarding "Forward-Looking" Information
Some of the statements contained in this news release are forward-looking statements and information within the meaning of applicable securities laws. Forward-looking statements and information can be identified by the use of words such as "expects", "intends", "is expected", "potential", "suggests" or variations of such words or phrases, or statements that certain actions, events or results "may", "could", "should", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements and information are not historical facts and are subject to a number of risks and uncertainties beyond the Company's control. Actual results and developments are likely to differ, and may differ materially, from those expressed or implied by the forward-looking statements contained in this news release. Accordingly, readers should not place undue reliance on forward-looking statements. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements, except as may be required by law.

SOURCE: BioNxt Solutions Inc.

View the original press release on accesswire.com

FAQ

What study did BioNxt complete for its Cladribine product?

BioNxt completed a comparative pharmacokinetic study for its Cladribine oral dissolvable film product.

What were the results of the pharmacokinetic study for BioNxt's Cladribine ODF product?

The study demonstrated rapid absorption and systemic exposure comparable to the name-brand reference drug.

What market segment is BioNxt targeting with its Cladribine ODF dosage form?

BioNxt is targeting the Multiple Sclerosis market segment with its Cladribine ODF dosage form.

How many people are estimated to be living with Multiple Sclerosis worldwide?

Approximately 2.3 million people are estimated to be living with Multiple Sclerosis worldwide.

What is the expected value of the global Multiple Sclerosis drug market by 2033?

The global Multiple Sclerosis drug market is expected to top USD 41 billion by 2033.

Where is BioNxt's subsidiary located?

BioNxt's subsidiary is located in the district of Biberach, Baden-Württemberg, Germany.

What is the value of the global pharmaceutical drug delivery market in 2022?

The global pharmaceutical drug delivery market size was valued at USD 1,525 billion in 2022.